Treatments for relapsed or refractory chronic lymphocytic leukemia
Relapsed, or recurrent, chronic lymphocytic leukemia (CLL) means that the cancer has come back after it has been treated.
Refractory CLL means that the cancer did not respond to treatment.
Your healthcare team will suggest treatments based on the molecular characteristics of the CLL cells. What you want will also be important when planning treatment.
The most common treatments used for relapsed or refractory CLL are targeted therapy and chemoimmunotherapy.
Targeted therapy uses drugs to target specific molecules (such as proteins) on cancer cells or inside them to stop the growth and spread of cancer. Chemoimmunotherapy combines chemotherapy with monoclonal antibodies, which are a type of targeted therapy. Chemotherapy uses drugs to destroy cancer cells.
CLL with del(17p) or TP53 mutation
If you have relapsed or refractory CLL that has a 17p chromosome deletion (the short arm "p" of chromosome 17 is missing) or a TP53 gene mutation (the TP53 gene has mutated, or changed), treatment is usually targeted therapy.
The most common targeted therapy drugs offered are:
- ibrutinib (Imbruvica)
- acalabrutinib (Calquence)
- zanubrutinib (Brukinsa)
- venetoclax (Venclexta)
-
VR – venetoclax and rituximab (Rituxan and
biosimilars )
Find out more about targeted therapy for CLL.
After trying different targeted therapies, you may also be offered a stem cell transplant if you are younger than 70 years old and meet the criteria set by your treatment centre. Find out more about stem cell transplant for CLL.
CLL without del(17p) or TP53 mutation
If you have relapsed or refractory CLL that does not have a 17p chromosome deletion or a TP53 gene mutation, treatment is usually targeted therapy.
The most common targeted therapy drugs offered are:
- venetoclax (Venclexta)
-
VR – venetoclax and rituximab (Rituxan and
biosimilars ) - ibrutinib (Imbruvica)
- acalabrutinib (Calquence) (may not be covered by all provincial or territorial health plans)
- zanubrutinib (Brukinsa) (may not be covered by all provincial or territorial health plans)
Find out more about targeted therapy for CLL.
If you are younger than 70 years old and have
A treatment option still being studied for relapsed or refractory CLL that does
not have a 17p chromosome deletion or a TP53 gene mutation is CAR T-cell
therapy. CAR T-cell therapy is a type of
Clinical trials
You may be asked if you want to join a clinical trial for CLL. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.
If you can't have or don't want cancer treatment
You may want to consider a type of care to make you feel better without treating the cancer itself. This may be because the cancer treatments don't work anymore, they're not likely to improve your condition or they may cause side effects that are hard to cope with. There may also be other reasons why you can't have or don't want cancer treatment.
Talk to your healthcare team. They can help you choose care and treatment for advanced cancer.
Your trusted source for accurate cancer information
With just $5 from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.
We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.
If everyone reading this gave just $5, we could achieve our goal this month to fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.